Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 1;8(8):919–930. doi: 10.1242/dmm.018580

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 2. — Effects of anti-VEGFR3 antibody treatment on renal lymphangiogenesis, inflammation and fibrosis. Quantification of renal cortical podoplanin-positive vessel-like structures of the rats who received treatment with anti-VEGFR3 antibody (IMC-3C5) showed a significant reduction of LV number at 12 weeks (A,B; 400×), whereas it showed a non-significant trend in reducing the number of macrophages in the cortical interstitium of proteinuric rats (C,D; 400×), and did not influence T-cell influx (E,F; 400×) at week 12. Anti-VEGFR3 antibody also did not have a significant effect on α-SMA (G,H; 200×), collagen III deposition (I,J; 200×) and interstitial fibrosis (K,L; 200×). White dotted bars represent week 6 before treatment; black bars represent week 12 after treatment. The PAS staining quantification (interstitial fibrosis) is showed at 12 weeks. HL, healthy; PR, proteinuric untreated; 3C5, anti-VEGFR3 antibody. *P<0.05, **P<0.01, ***P<0.001.